MAPT and Alzheimer disease: Patients with cognitive symptoms and decreased CSF Aβ42 without pathological amyR nor increased p-tau levels could, under certain circumstances, be essentially considered non-AD, but this conclusion can be hard to reach when clinical presentation and FDG-PET pattern are highly suggestive of AD.